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SHORT REPORT
New digital tool to facilitate 
subcutaneous insulin therapy orders: an 
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Abstract 
Background: Inpatient hyperglycemia is associated with adverse outcomes in hospitalized patients, with or without 
known diabetes. The adherence to American College of Endocrinology and American Diabetes Association guide-
lines recommendations for inpatient glycemic control is still poor, probably because of their complexity and fear of 
hypoglycemia.
Objective: To create software system that can assist health care providers and hospitalists to manage the insulin 
therapy orders and turn them into a less complicated issue.
Methods: A software system was idealized and developed, according to recommendations of major consensus and 
medical literature.
Results: HTML software was developed to be readily accessed from a workstation, tablet or smartphone. Standard 
initial daily total dose of insulin was 0.4 units/kg and could be modified by distinct factors, such as chronological age, 
renal and liver function, and high dose corticosteroids use. Insulin therapy consisted of basal, prandial and correc-
tion insulin according to nutritional support, glycemic control and outpatient treatment for diabetes. Human insulin 
or insulin analogues could be options for insulin therapy. Sensitivity factor was based on 1800 Rule for rapid-acting 
insulin and the 1500 Rule for short-acting insulin. Insulin-naïve patients with initial BG level less than 250 mg/dL 
were considered to have an initial step-wise approach with prandial and correction insulin. The calculator system has 
allowed insulin dose readjustments periodically, according to daily average blood glucose measurements.
Conclusion: We developed software that can be a useful tool for all public hospitals, where generally human insulin 
is the only available.
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Brief report
Inpatient hyperglycemia is associated with adverse clini-
cal outcomes in hospitalized patients, with or without 
known previous diabetes mellitus (DM), including pro-
longed hospital stay, infection, disability after hospital 
discharge, death and higher health care costs [1–4]. Even 
in patients without DM, hyperglycemia may be an acute 
manifestation of critical and surgical illness that results 
from the metabolic and hormonal changes, in response 
to injury and stress [2].
The American College of Endocrinology (ACE) and 
the American Diabetes Association (ADA) Task Force 
on Inpatient Glycemic Control recommend fasting blood 
glucose (BG) level less than 140 mg/dL (7.8 mmol/L) and 
a random BG level less than 180 mg/dL (10.0 mmol/L), 
without excess hypoglycemia, for the majority of non-
critically ill patients treated with insulin. In order to avoid 
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were considered if BG levels decline below 100  mg/dL 
(5.6  mmol/L). It was suggested for BG testing: before 
meals and at bedtime in patients who were eating, or 
every 4–6  h in patients who were receiving nothing by 
mouth (nil per os—nPO) or receiving continuous enteral 
feeding [4]. Despite the fact that many studies have 
shown solid evidence in support of inpatient glycemic 
control, BG control remains deficient and overlooked [2].
Subcutaneous insulin is the preferred therapeutic agent 
for BG control in hospitalized patients in non-critical 
care setting [2, 5, 6]. The sliding scale insulin (SSI) is the 
most commonly chosen insulin therapy regimen. How-
ever, this regimen results in great glycemic variability 
with undesirable levels of hypoglycemia and hyperglyce-
mia [5]. Clinical practice guidelines have recommended 
the use of insulin regimen with combined basal and short 
or rapid-acting insulin (basal bolus approach) as the pre-
ferred insulin regimen for the management of hypergly-
cemia in hospitalized patients in non-critical care setting. 
Basal bolus insulin therapy based on BG results is safe 
and efficacious in the management of inpatient hypergly-
cemia [11].
Despite the benefits of a basal bolus regimen in improv-
ing glycemic control in non-critically ill patients, many 
health care providers are still reluctant to integrate this 
approach into their clinical practice, probably because of 
its complexity and a fear of hypoglycemia. Moreover, the 
management of diabetes in the hospital is generally con-
sidered less important compared with the condition that 
prompted admission and clinical inertia rules in glycemia 
management in the hospital [7–9]. In Brazil, the inpatient 
BG management is also deficient, whereas DM is the fifth 
most common reason for hospitalizations and ranked 
among the 10 major causes of mortality [3]. Recently, we 
analyzed 368 hospitalized patients at Hospital das Clíni-
cas da Faculdade de Medicina da Universidade de São 
Paulo and 23 % of patients had previous diagnosis of dia-
betes mellitus, but only 1 % of them had received basal-
bolus as insulin therapy regimen [10].
There is still a lack of clinical studies on the use of 
neutral protamine Hagedorn (NPH) and regular insu-
lin (available in public health care system in Brazil) for 
inpatient treatment of hyperglycemia. Most of prospec-
tive randomized studies used insulin analogues as insu-
lin therapy for hospitalized patients. Randomized studies 
showed that a basal bolus regimen with insulin analogues 
resulted in equivalent glycemic control and frequency of 
hypoglycemia compared to treatment with human insu-
lin. The number of episodes of hypoglycemia less than 
40  mg/dL was low in both groups, but not statistically 
significant higher in the group with NPH and regular 
insulin [11, 12].
The relationship between hyperglycemia and hospital 
outcomes is well-established [8] and major consensus 
recommends that insulin therapy should be prescribed 
for all patients with hyperglycemia, preferentially with 
basal-bolus regimen. Accordingly, we previously imple-
mented a paper-based glycemic control protocol in hos-
pitalized patients that works with flowcharts and tables, 
the same way as most of hospitals has done. Because of 
the adherence had been still low, we idealized a software 
program that could assist the health care providers and 
hospitalists to manage the insulin therapy orders in the 
hospital setting and turn them into a less complicated 
issue. The software was developed as an HTML appli-
cation that can be readily accessed through a network 
using a workstation, tablet or smartphone. It could be 
run on Windows PC, Macintosh, iOS or Android devices 
(Figs. 1, 2).
In this new software system, glycemic targets were 
defined according to ACE/ADA guidelines. Average BG 
between 100 and 140 mg/dL was defined as target for the 
non-critically ill-patients BG control.
The category dose insulin was defined to become 
easier to remind the total daily dose of insulin (TDDI). 
The standard TDDI was 0.4 units/kg and was defined as 
insulin dose category number ´8´. One category could 
be increased or decreased by 0.05  units/kg, according 
to modifier factors described ahead. A lower category 
dose was considered for patients at risk of hypoglyce-
mia, such as elderly patients or those with renal or liver 
impairment. Higher dose was considered for patients 
with higher insulin resistance, such as obese patients or 
those in use of high dose of corticosteroids [9, 13]. Every 
modifier factor could affect the insulin dose category 
independently and the final category was defined accord-
ing to their combination. BG testing was recommended 
before meals and at bedtime in patients who were eating, 
or every 6  h in patients who were receiving nothing by 
mouth (nil per os—NPO) or receiving continuous enteral 
feeding (Fig. 1).
Scheduled subcutaneous insulin therapy consisted of 
the following components: basal insulin administered as 
NPH insulin twice or three times a day or glargine and 
detemir insulin once a day; and prandial and correc-
tion insulin administered as short-acting (regular) or 
as rapid-acting insulin (lispro, aspart, glulisine) prior to 
major meals (breakfast, lunch and dinner) or four times 
a day (every 6 h), if NPO or with enteral feeding. Hyper-
glycemic or DM patients who were eating received about 
50 % of the TDDI as basal insulin and 50 % as prandial 
(or nutritional) insulin in divided doses administered 
with major meals (basal-bolus regimen). Correction dose 
was combined with prandial insulin dose to compensate 
Page 3 of 6Toyoshima et al. Diabetol Metab Syndr  (2015) 7:114 
for hyperglycemia before meals. Patients who were not 
eating (at NPO status) were considered to receive basal 
(50 % of the TDDI) and correction-dose insulin, as well 
called basal plus regimen [14]. The prandial insulin dose 
was withdrawn. Patients who were insulin-naïve or in use 
of outpatient insulin treatment with total daily dose less 
than 0.2 IU/kg, and initial BG level less than 250 mg/dL 
(14.4 mmol/L), an initial step-wise approach was consid-
ered with prandial insulin and correction dose (Fig.  3). 
After revaluation in 24–48 h, basal insulin was included 
if average BG has been more than 180 mg/dL [15]. To cal-
culate the sensitivity (or correction or supplemental) fac-
tor and consequently correction insulin-dose, the 1800 
Rule for rapid-acting insulin, and the 1500 Rule for short-
acting insulin were used [16].
Patients that were eating and had hyperglycemia at 
bedtime, supplemental rapid or short-acting insulin was 
recommended as follow: two units for BG 250–350 mg/
Fig. 1 Screenshot of the application showing an example of initial management of patient with hyperglycemia and the respective prescription
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dL (13.9–19.4 mmol/L) and four units for BG more than 
350 mg/dL (more than 19.4 mmol/L). A randomized trial 
of insulin supplementation for correction of inpatient 
bedtime hyperglycemia didn’t show that bedtime insu-
lin dose to correct mild and moderate hyperglycemia 
(less than 350 mg/dL) in patients under basal-bolus regi-
men was not associated with significant improvement in 
glycemic control or frequency of hypoglycemia episodes 
[17].
Some safety alerts were associated with the program to 
help to recognize diabetes emergencies. It has been avail-
able specific orders for hypoglycemia episodes, including 
glucagon use if patient was not alert and with no periph-
eral intravenous line. If any blood glucose measurement 
Fig. 2 Screenshot of the application showing an example of follow-up of blood glucose measurements and the respective prescription with adjust 
of insulin regimen or dose
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has been more than 250  mg/dL, a message to rule out 
diabetes ketoacidosis has been shown up. Insulin dose 
readjustments were recommended to be done within 
24–48  h (Fig.  2). If average BG has been more than 
140  mg/dL, the insulin dose category was increased. In 
case of average BG measurements less than 100 mg/dL, 
the software has recommended to reduce the insulin 
dose category. For patients with great glycemic variabil-
ity, defined as hypoglycemia and hyperglycemia episodes 
in a short period of time, the software has recommended 
to consider Endocrine or Diabetes Team Consultation to 
individualize the treatment.
In conclusion, we developed the first Brazilian appli-
cation software that can use human insulin (NPH and 
regular) or insulin analogues (glargine, detemir, lispro, 
aspart and glulisine) as options for inpatient hypergly-
cemia management, and therefore it can be a useful tool 
for all public hospitals. We hope it can assist the health 
care providers and hospitalists to manage the insulin 
therapy orders in the hospital setting, and turn them 
into a less complicated issue, with improved adherence 
to guidelines recommendations. The software did not 
replace the physicians and their decisions, but could act 
to extend their knowledge and to help with the insulin 
dose prescription. Further studies are still necessary to 
assess this electronic-based insulin protocol adherence.
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Fig. 3 Initial insulin therapy for hyperglycemia in hospitalized patients. Insulin therapy regimen was chosen according to initial blood glucose, out-
patient diabetes treatment and nutritional support. A step-wise approach was considered for patients who were insulin-naïve, in use of outpatient 
single-dose insulin treatment and with initial BG level less than 260mg/dL
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